ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
(b)On March12, 2018, Dr.Michael Weiser resigned from the board of directors, or the Board, of Ziopharm Oncology, Inc., or the Company, including all committees thereof, effective immediately.
Effective March12, 2018, the Board appointed James Cannon to serve on the Board’s compensation committee. Following such appointment, the members of the compensation committee are Scott Tarriff, who will serve as the committee’s chairman, Dr.Murray Brennan and James Cannon.
About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.
